Dua puluh enam pendeita dengan hepatitis kronik C (HKC) yang knmbuh atau tidnk berespons setelah terapi interferon (IFN) telah dibeikan terapi iombinasi IFi atfa -2b 3 juta unit tiga kali seminggu dengan ribavirin (RIB) 800-1000 mg sehai selama 48 minggu' Dua puluh saiu (gl7o) dai 26 paiien dapat menyelesaikan studi ini terdii dari 12 pasien kambuh dan 9 tidakberespon sedangkan 5 pasiin keluar dari studi karenà eyek samping pada 3 pasien dan 2 lainnya tidak berhubungan dengan terapi. Pada kelompok kambuh 'respon lengkap, kambuh dan respons perrnanen masing-masing didapatkan pada 9/12 (75Eù, 2/12 (I7Vo) dan 7/12 (587a) pasien.
I/g(I1,1Eo), and 2/9(22,2Vo) pts, respectively. The most fiequent adverse event was flu-like syndrome, which was found in 18 Mean duration of previous IFN tberapy (month) 7 .l "Flu-like" symptoms (fatigue, fever, arthralgia, myalgia, and headache) were the most common adverse events and were observed in 69Vo of patients. Mental symptoms such a5 insomnia, sleepy, and psychiatric disturbance were recorded in l57o of patients. There were no sings of specific adverse events associated with longer retreatment. Our study has revealed that some patients developed decrease of hemoglobin levels during the combination treatment. Since the average body weight of our patients is less compared to that of patients in western countries, 600 to 800 mg ribavirin daily might be sufficient.
DISCUSSION
In conclusion, the present data show that combination IFN and RIB for 12 months is safe and effective in inducing sustained virologic response in relapsed or non-responding chronic hepatitis C patients. However, still low response rate in non-responders indicates a need for better therapeutic options.
